文献速递肺血管病与心包/心肌炎

肺血管疾病中的铁缺乏:病理生理与临床意义

Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.
PubMed 文献 · Eur Heart J · 2023-01-01

本研究分析1028例肺高压患者,比较心衰定义与TSAT<21%对铁缺乏的识别能力。心衰定义未能识别运动能力下降者,而TSAT<21%可识别peakVO2、6分钟步行距离和SF-36评分更差的患者,并与右心室重构及死亡率增加相关。

要点

  • 心衰定义铁缺乏不能识别肺高压患者运动能力下降。
  • TSAT<21%可识别运动能力、功能状态更差及右心重构患者。
  • TSAT<21%与调整后死亡率风险增加独立相关。

核心结论

  • 2022 ESC/ERS肺高压指南的铁缺乏定义不能识别运动能力或功能状态较差的患者,而TSAT<21%可识别运动能力更低、功能状态更差、右心重构及不良临床结局的患者。

研究设计与样本

  • 分析Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics研究中1028例患者的表型数据。
  • 铁缺乏分别采用传统心衰定义和基于peakVO2、6分钟步行距离及SF-36评分最佳切点定义。

主要发现

  • 心衰定义铁缺乏未识别peakVO2、6分钟步行距离及SF-36降低的患者(所有P>0.208)。
  • TSAT<21%者较TSAT≥21%者peakVO2绝对差值为-1.89(-2.73至-1.04)mL/kg/min,6分钟步行距离绝对差值为-34(-51至-17)m,SF-36躯体成分评分绝对差值为-2.5(-1.3至-3.8),均P<0.001。
  • TSAT<21%者心脏磁共振显示更多右心室重构,但导管检查肺血管阻力相似。
  • 调整性别、年龄、血红蛋白和NT-proBNP后,TSAT<21%与死亡率风险增加相关(HR 1.63,95%CI 1.13-2.34;P=0.009)。

关键数值与推荐

  • 传统心衰定义铁缺乏未识别运动能力或功能状态降低(P>0.208)。
  • TSAT<21%定义铁缺乏可识别peakVO2、6分钟步行距离及SF-36躯体成分评分降低(均P<0.001)。
  • TSAT<21%与调整后死亡率风险增加相关(HR 1.63,95%CI 1.13-2.34;P=0.009)。

临床怎么用

  • 在肺高压患者中评估铁缺乏时,TSAT<21%可能比传统心衰定义更能识别运动能力下降和不良预后风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Iron deficiency is common in pulmonary hypertension, but its clinical significance and optimal definition remain unclear. METHODS AND RESULTS: Phenotypic data for 1028 patients enrolled in the Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics study were analyzed. Iron deficiency was defined using the conventional heart failure definition and also based upon optimal cut-points associated with impaired peak oxygen consumption (peakVO2), 6-min walk test distance, and 36-Item Short Form Survey (SF-36) scores. The relationships between iron deficiency and cardiac and pulmonary vascular function and structure and outcomes were assessed. The heart failure definition of iron deficiency endorsed by pulmonary hypertension guidelines did not identify patients with reduced peakVO2, 6-min walk test, and SF-36 (P > 0.208 for all), but defining iron deficiency as transferrin saturation (TSAT) <21% did. Compared to those with TSAT ≥21%, patients with TSAT <21% demonstrated lower peakVO2 [absolute difference: -1.89 (-2.73 to -1.04) mL/kg/min], 6-min walk test distance [absolute difference: -34 (-51 to -17) m], and SF-36 physical component score [absolute difference: -2.5 (-1.3 to -3.8)] after adjusting for age, sex, and hemoglobin (all P < 0.001). Patients with a TSAT <21% had more right ventricular remodeling on cardiac magnetic resonance but similar pulmonary vascular resistance on catheterization. Transferrin saturation <21% was also associated with increased mortality risk (hazard ratio 1.63, 95% confidence interval 1.13-2.34; P = 0.009) after adjusting for sex, age, hemoglobin, and N-terminal pro-B-type natriuretic peptide. CONCLUSION: The definition of iron deficiency in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension guidelines does not identify patients with lower exercise capacity or functional status, while a definition of TSAT <21% identifies patients with lower exercise capacity, worse functional status, right heart remodeling, and adverse clinical outcomes.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Martens P, Yu S, Larive B, et al. Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications. Eur Heart J. 2023. PMID: 36879444. doi:10.1093/eurheartj/ehad149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。